Vatera Healthcare Partners
VC Fund
New York, United States
Vatera Healthcare Partners is a private equity and venture capital firm specializing in investments in healthcare.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Vatera Healthcare Partners invests in
Stages Vatera Healthcare Partners invests in
Countries Vatera Healthcare Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Antonio M. Gotto Jr
|
|||
|
|
|||
|
Christopher William Burden
|
|||
|
Howard B. Dean
|
|||
|
Kevin Thomas Ferro
|
|||
| See all 10 contacts → | |||
Investment Focus
Industry
- Biotechnology 3 (21%)
- Health Care 2 (14%)
- Medical 1 (7%)
- Therapeutics 1 (7%)
- Pharmaceutical 1 (7%)
Stage
- Series C 2 (14%)
- Series A 1 (7%)
- Series B 1 (7%)
- Series D 1 (7%)
- Funding Round 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Antonio M. Gotto Jr
Director
|
Director | Total investments: 0 | Find email | |
|
Christopher P. Kiritsy
Director
|
Director | Total investments: 3 | Find email | |
|
Christopher William Burden
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
Howard B. Dean
Director
|
Director | Total investments: 0 | Find email | |
|
Kevin Thomas Ferro
Founder, Chief Executive Officer
|
Founder, Chief Executive Officer | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating,preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy.ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts. | $40M / Series C / Nov 14, 2017 | ||
| Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issuesfacing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. | $67M / Post-IPO Equity / Jun 10, 2015 | ||
| ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating,preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy.ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts. | Series B / Dec 22, 2014 | ||
| Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issuesfacing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. | $70M / Post-IPO Equity / Feb 10, 2014 | ||
| Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes. | $41.7M / Apr 01, 2013 | ||
| Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issuesfacing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. | $67.5M / Post-IPO Equity / Nov 29, 2012 | ||
| Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes. | $65M / Series D / Nov 13, 2012 | ||
| Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes. | $23.3M / Private Equity / Oct 01, 2012 | ||
| ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating,preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy.ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts. | Series A / Dec 13, 2011 | ||
| Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes. | $69M / Series C / Oct 19, 2010 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Vatera Healthcare Partners invest in?
Vatera Healthcare Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vatera Healthcare Partners?
Public channels for Vatera Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vatera Healthcare Partners?
The team at Vatera Healthcare Partners includes Antonio M. Gotto Jr (Director), Christopher P. Kiritsy (Director) and Christopher William Burden (Chief Operating Officer), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!